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Highlights: 11 
• The lyophilic matrix (LM) method for dissolution and release studies of powders, nanoscale 12 
particles, and particulate systems is introduced. 13 
• LM method avoids major issues encountered with current dissolution methods such as the 14 
membrane effect and dispersion of the non-dissolved particles. 15 
• LM method permits rapid contact with the dissolution medium, enables separating the dissolved 16 
species from the non-dissolved particles, and clearly displays the different dissolution rate of different 17 
size particles. 18 
Abstract 19 
We introduce a system with a lyophilic matrix to aid dissolution studies of powders and particulate 20 
systems. This lyophilic matrix method (LM method) is based on the ability to discriminate between 21 
non-dissolved particles and the dissolved species. In LM method the test substance is embedded in a 22 
thin lyophilic core-shell matrix. This permits rapid contact with the dissolution medium while 23 
minimizing dispersion of non-dissolved particles without presenting a substantial membrane effect. 24 
The method produces realistic dissolution and release results for particulate systems, especially those 25 
featuring nanoscale particles. By minimizing method-induced effects on the dissolution profile of 26 
nanopowders, the LM method can overcomes shortcomings associated with current dissolution test 27 
methods.   28 
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1. Introduction 34 
The dissolution rate of a drug is a physico-chemical property to be determined and modified during 35 
drug discovery and development [1, 2]. For example, reducing the particle size to the nanoscale 36 
increases the dissolution rate and thus the bioavailability of poorly water-soluble drugs in classes II 37 
and IV of the Biopharmaceutics Classification System [3-5]. The dissolution rate of nanoscale 38 
particles correlate with the performance and quality of a formulation featuring nanoparticles [3]. 39 
Hence to assess the impact of nanonizing a poorly water-soluble drug, one needs reliable dissolution 40 
rate data of nanoparticulate systems. Such data could allow one to predict realistic in vitro - in vivo 41 
(IVIV)-correlation and facilitate determination of dose in animal experiments [6-8]. 42 
Current methods for investigating dissolution rates of nanoscale particles include the United States 43 
Pharmacopoeia (USP) I (basket), II (paddle), and IV (flow-through) methods, as well as modifications 44 
thereof, membrane diffusion methods (such as the dialysis methods), and sample and separate 45 
methods (such as centrifugal ultrafiltration) [6, 7, 9-14]. Additionally, dissolution rates of 46 
nanoparticles have been determined from tablets and admixtures using gel matrices [15, 16].Often, 47 
the measured values reflect features of the dissolution test device, equipment or method, rather than 48 
the nanoparticle properties.   49 
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The main issues with the current methods include: dispersion of non-dissolved particles, 50 
hydrodynamics-induced variability, membrane effects caused by diffusion barriers (e.g. gelatin, 51 
filters, or dialysis membranes), clogging and breaking of filters, sensitivity to flow and location in the 52 
dissolution vessel, as well as migration of nanoparticles to interfaces (e.g. wetting issues, floating, or 53 
adhesion) [17-24]. The UPS methods were not designed for dissolution studies of nanoscale particles 54 
and thus produce unrealistic results [13, 17]. Dispersion and the consequent overestimation of 55 
nanoparticle dissolution rates in the USP I and II methods occur when the location of the particles is 56 
not fixed. In the USP IV method dispersion occurs when a too large filter pore size is used [6]. On 57 
the other hand, constraining diffusion of the dissolved species by membranes or encapsulation, leads 58 
to measurement of the quality of the diffusion barrier rather than the nanoparticle dissolution, and 59 
often to underestimating the dissolution rate [17, 19, 25, 26]. Using tablets or admixtures may alter 60 
the physical form of the drug during the tableting or mixing processes, and they may detach particles 61 
from the tablet surface during the dissolution process, or induces a diffusional barrier [15, 16]. 62 
Accordingly, there is a need for new methods and devices for determining dissolution rates of 63 
nanoparticles. 64 
2. Materials and methods 65 
2.1. Chemicals 66 
Indomethacin (Hawkins, USA) was used as poorly water-soluble model compound in the dissolution 67 
experiments and poloxamer 188 (BASF Co., Germany) was used as stabilizer. The chemicals used 68 
for preparing the media for the dissolution studies were monopotassium phosphate (Riedel-de Haën, 69 
Germany), sodium phosphate dibasic (Sigma-Aldrich, USA), and 5M sodium hydroxide (VWR 70 
Chemicals BDH Prolabo, EC). All chemicals employed in the experiments were of analytical grade 71 
and used as received.  72 
2.2. Structure of the device 73 
The device used in the dissolution experiments comprised a lyophilic matrix, a cage, a vessel, and a 74 
mixing/heating plate (Fig. 1). The matrix has a core-shell structure comprising a core matrix, that 75 
contained the particles of the test substance, and a surrounding shell matrix. The matrix material of 76 
both core and shell matrices is cotton (100% cotton, Curatex GmbH, Germany). The shell matrix 77 
consists of four layers of water jet-pressurized cotton with a dry specific surface weight of 5 ± 0.2 78 
mg/cm2. Cotton was selected as matrix material due to its unique properties; hollow cellulose fibers, 79 
high wet strength, inert nature, and substantial ability to absorb water-based media.  The custom 80 
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designed stainless steel cages (depth 3 mm x height 26 mm x width 16 mm) were 3D printed with 81 
selective laser sintering (Mlab Cusing, Concept Labs, Germany). The cage maintained the desired 82 
matrix geometry and provided a fixed diffusion distance. 83 
 84 
Fig. 1. a) LM method test setup and b) core-shell structure within the LM device, blue dots represent 85 
the core matrix containing the particles surrounded on all sides by the shell matrix and cage. 86 
2.3. Characterization of the matrix 87 
2.3.1. Matrix-medium interaction  88 
The cotton matrix was examined prior to, during, and after medium exposure with light microscopy 89 
(Leica DMLB, Leica Microsystems Wetzlar, Germany) with a magnification of 200 x, and prior to, 90 
and after medium exposure with scanning electron microscopy (SEM, Quanta™ 250 FEG, FEI Inc., 91 
USA) with a magnification of 500 x, voltage of 5.00 kV, spot size of 3.0, sputter coated with a 5-nm-92 
thick platinum layer (Q150T Quomm, Beijing, China). The water up-take properties of the matrix 93 
were investigated with a fast camera (1200 fps, Casio Exilim High-speed EX-FI1, Casio, Japan) and 94 
by weighing the matrix prior to and after exposure to the medium.  95 
2.3.2. Drug-matrixn interaction  96 
The partitioning of the model compound between the matrix and medium was examined by partition 97 
coefficient and inverse partitioning coefficient studies. First, the retention of the model compound 98 
within the matrix was examined. This was done by partition coefficient tests, where the matrix 99 
containing 1 mg of bulk indomethacin was immersed in the medium, and collected after 22 hours. 100 
5 
 
  
The indomethacin retained in the matrix was determined by immersing the matrix into fresh medium 101 
for 22 hours. This procedure was conducted with three parallel experiments in pH 5.5 and pH 7.4 102 
phosphate buffer media [27] at 37.0 ± 0.5 °C with a stirring rate of 180 rpm (IKA RT 15 P, IKA 103 
Werke GmbH & CO. KG, Germany). The concentration of the medium was determined after first 104 
and second immersion at time point of 22 h. The concentration of the samples was analyzed with high 105 
performance liquid chromatography (HPLC Thermo System Products, Agilent 1200 Infinity Series, 106 
Agilent Technologies, Germany), using a Discovery C18 column (4.6 × 150 mm, 5 μm, Supelco, 107 
USA), 1.5 mL/min flow rate with a mobile phase consisting of 60:40 (V/V) acetonitrile (ACN) and 108 
0.2% ortophosphoric acid (H3PO4) in water (MilliQ), operating at 30 °C with detection at 270 nm. 109 
The standard curve for indomethacin quantification was acquired from triplicate samples of 110 
indomethacin concentrations between 0.08 mg/L and 500 mg/L (R2 = 0.999).  111 
Second, the partitioning of the dissolved species into the matrix was examined. This was done by 112 
inverse partition coefficient tests, where an empty matrix was inserted into medium with saturated 113 
concentration of the model compound. Test was conducted in triplicate in phosphate buffer media 114 
with pH of 5.5 and 7.4. The empty matrices were inserted into the medium every 5 minutes and the 115 
test run was 20 minutes. The concentration of the medium was monitored online using in-situ fiber-116 
optic UV monitoring (Opt-Diss 410, Distek, Inc., USA) using probes with a path-length of 5 mm, 117 
exposure time of 44 ms (4 scans/data point) at an analytical wavelength of 320 nm.     118 
 119 
2.4. Drug release studies  120 
2.4.1. Preparation and characterization of the particles  121 
A nanosized fraction, two sieved particle size fractions, and bulk indomethachin were tested with the 122 
LM method. Nanosuspension was prepared by milling with a Fritsch Pulverisette 7 Premium ball mill 123 
(Fritsch GmbH, Germany) to obtain particles for the experiments. Nanoparticles for the LM method 124 
were prepared of 2 g indomethacin suspended in solution containing 5.0 mL 0.24 g/mL poloxamer 125 
188 solution (60 wt% relative to the drug amount) and 5.0 mL water (milliQ), and by grinding at 850 126 
rpm in 5 cycles of 3 min using 60 g milling pearls (zirconium oxide, diameter 1 mm). The particle 127 
size distribution in the nanosuspension was determined with a Zetasizer Nano SZ (Malvern 128 
Instruments Ltd., UK). 129 
The bulk indomethacin was divided into two fractions using a sieve with an eye size of 125 µm 130 
(Fritsch GmbH, Germany). The particle size of the bulk powder and the two fractions were 131 
determined from SEM images (see section 2.3.1.) (n = 300, ImageJ freeware, National Institutes of 132 
6 
 
  
Health, USA). The bulk powder and the two fractions were each mixed with poloxamer 188 (60 wt% 133 
relative to the drug amount) to achieve physical mixtures with components identical to the 134 
nanosuspension.  135 
2.4.2. Dissolution experiments 136 
The test substances (corresponding to 400 µm of indomethacin) were distributed within the core 137 
matrix, the nanosuspension was distributed wet and left to dry. The core matrix was then placed in 138 
the matrix holder. Dissolution tests were conducted in triplicate for nanoparticles, bulk powder, and 139 
the two particle size fractions in pH 5.5 phosphate buffer medium [27] and for nanoparticles and bulk 140 
powder in pH 7.4 phosphate buffer medium [27]. All tests were performed under sink conditions in 141 
100 mL of dissolution medium at 37.0 ± 0.5 °C using a stirring rate of 180 rpm (IKA RT 15 P, IKA 142 
Werke GmbH & CO. KG, Germany). The stirring rate and the geometry of the matrix were optimized 143 
with preliminary experiments. Aliquots of 1 mL, subsequently replaced with the same volume of 144 
fresh medium, were taken at 12 time points: 30 s, 1 min, 2 min, 5 min, 10 min, 30 min, 1 h, 2 h, 3 h, 145 
4 h, 6 h, and 22 h. The samples were analyzed with HPLC as described in section 2.3.2. Cumulative 146 
release of indomethacin and standard deviation in three parallel samples were determined for each 147 
experiment. 148 
3. Results and discussion  149 
3.1. Properties of the matrix 150 
3.1.1. Matrix-medium interaction 151 
No visual changes were detected in the size, topology, and morphology of the cotton fibers as the 152 
matrix was exposed to dissolution medium, nor did the structure of the cotton change after drying 153 
(Fig. 2). When immersed into medium, the cotton matrix was wetted in 0.31 s ± 0.10 s. The matrix 154 
withdrew medium approximately 23 times its weight. The result of these two experiments indicate 155 
that the particles within the matrix are exposed to the medium immediately after immersion. The 156 
volume of the matrix increases when exposed to medium. However, microscope studies indicated 157 
that the single fibers do not swell when immersed into the medium.  158 
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 159 
Fig. 2. Light microscope images of the cotton shell matrix a) prior to dissolution medium exposure, 160 
b) exposed to medium, and c) after medium exposure. SEM images of the cotton d) prior to medium 161 
exposure, and e) after medium exposure. Scale bars correspond to 200 µm.  162 
3.1.2. Drug-matrix interaction  163 
No retained indomethacin was found in the matrix after first 22 hours of in the partition coefficient 164 
tests. The concentrations obtained were below the detection limit (0.08 mg/L) of the HPLC method. 165 
This indicates that > 99.2 % of indomethacin is released from the matrix and the dissolved species is 166 
not significantly retained within the matrix. The inverse partition coefficient test showed no 167 
detectable (detection limit: ____) change in concentration when the matrix was immersed into the 168 
medium with dissolved indomethacin. This indicates that the matrix does not absorb dissolved 169 
indomethacin from the dissolution medium. 170 
As shown in the characterization tests, the matrix is practically inert and has little effect on the total 171 
quantity of indomethacin released (Table 1). As the pH has no effect on the partition coefficient, we 172 
conclude that at least with indomethacin - a weak acid (pKa 4.5) - the change in the pH of the medium 173 
causes no adsorption onto the fibers. The partitioning coefficient studies were conducted only in 174 
regard to the dissolved species. The possible adhesion is not considered to be an issue, since the non-175 
dissolved particles are intended to remain within the matrix.  176 
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Table 1 177 
Summary of the investigated properties of the matrix.  178 
Property Experiment Result 
Intake of medium Weighing  23 x weight of the matrix 
Wetting time Fast camera tests 0.31 ± 0.10 s 
Impact of medium on morphology Imaging no impact 
Adsorption of dissolved species to 
matrix (from particles) 
Partition coefficient > 99.2 % 
Adsorption of dissolved species to 
matrix (from media) 
Inverse partition 
coefficient 
< ___ % 
3.2. Drug release studies 179 
3.2.1. Particle size 180 
The average size of the nanoparticles was 424 nm ± 236 nm, and of the bulk powder 20.3 µm ± 30.0 181 
µm, featuring size range of 1 µm - 272 µm. The average size of the small fraction was 17.4 µm ± 182 
11.6 µm, and of the large fraction 22.1 µm ± 21.8 µm.  183 
3.2.2. Dissolution rate 184 
Differences in dissolution rate as function of particle size and pH were evident in the dissolution 185 
profiles obtained with LM method. Fig. 3 shows the cumulative release of indomethacin nanoparticles, 186 
small and large size fraction in pH 5.5, and nanoparticles and bulk indomethacin in pH 7.4 up to 30 187 
min. The short lag times indicated rapid wetting of the samples and absence of any significant 188 
membrane effect. Monotonously increasing dissolution profiles and constant standard deviations 189 
indicate that the variation between aliquots is moderate, i.e. that no substantial withdrawal of particles 190 
occurred during sampling. The method was accurate with small sample quantities and differences 191 
between the dissolution rates were detected within 5 minutes from the start of the experiment as seen 192 
in the dissolution profiles. 193 
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 194 
Fig. 3. Cumulative release (%) of indomethacin a) nanoparticles, small fractions and large fraction in 195 
pH 5.5 up to 30 min  and 5 min at 37.0 ± 0.5 °C, b) nanoparticles and bulk in pH 5.5 and 7.4 up to 30 196 
min  and 5 min at 37.0 ± 0.5 °C. Error bars are standard deviations of three parallel measurements.   197 
3.3. Principle of the LM method 198 
The key factor of the LM method is its ability to separate non-dissolved particles from dissolved 199 
species and its ability to prevent dispersion of the particulates without presenting a significant 200 
membrane effect. The dissolved species exit the matrix, whereas the non-dissolved particles remain 201 
within the matrix (Fig. 4). 202 
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 203 
Fig. 4. Dissolved species (small spheres) diffuse promptly into the medium, whereas the diffusion 204 
velocity of the non-dissolved species (medium size and large spheres) is lower. Smaller particles 205 
(medium size spheres) dissolve to form the dissolved species faster than larger particles (large 206 
spheres). 207 
Instead of dispersing the particles into the dissolution medium or exchanging the medium through a 208 
barrier, the matrix fixes the position of the non-dissolved particles and brings the medium to the 209 
particles. In the LM method the particles are dissolved from a stationary point in a semi 2-dimensional 210 
system under sink conditions. The efficient intake of medium, the concentration gradient, and the 211 
mild convection induced in the vessel drive the dissolved species out of the matrix. The matrix does 212 
not a form a separate compartment in the dissolution vessel and the lack of interaction between the 213 
cotton fibers and the model compound ensures that the dissolved species is not trapped in the matrix.  214 
The dissolution of the particles within the matrix is initiated as the matrix absorbs medium. The whole 215 
particle population is wetted nearly simultaneously. The dissolution rate depends on the active surface 216 
area of the particles as described by the Nernst-Brunner equation and the radius and particle curvature 217 
as described by the Gibbs-Kelvin equation [28-30]. The equations predict that small particles dissolve 218 
faster than large ones. 219 
Results produced by the LM method do neither overestimate the dissolution rates nor do they induce 220 
substantial lag times. The ability to produce realistic dissolution data supports early formulation 221 
development, which is valuable for evaluation of advantages gained by particle size reduction and 222 
nanonization. Small sample-to-sample variation enables producing reliable results with small inter- 223 
or intra-laboratory variation. Thus, it can be inferred that dissolution testing with lyophilic matrices 224 
produces realistic estimates of dissolution rates of nanoscale particles. Further studies are needed to 225 
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prove the universal applicability of the LM method and to assess the dissolution rate for different 226 
substances as well as to verify the IVIV-correlation. 227 
4. Conclusions 228 
The LM method developed in this study is suitable for determining dissolution rates of particulate 229 
systems, especially of nanoscale particles. The method features short lag time, small sample-to-230 
sample variation, and monotonously increasing dissolution profiles. It was capable to discriminate 231 
the dissolution rates of the tested particle size fractions. The inert cotton matrix used enables release 232 
studies without any substantial membrane effect, avoiding dispersion of the non-dissolved particles, 233 
and providing rapid wetting of the sample. 234 
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